Eucrates Biomedical Acquisition Corp.
We intend to focus on industries that complement our management team’s background, and capitalize on the ability of our management team to identify and acquire a business, focusing on the biomedical or healthcare-related industries. In particular, we will target North American and European healthcare companies with the potential to drive transformational change through the convergence of biomedicine and data science, areas in which our management team and Board of Directors have extensive operating, investing and transactional experience.
Dr. Stelios Papadopoulos, the chairman of our board of directors, is chairman of the board of directors of Biogen Inc., Exelixis, Inc., and Regulus Therapeutics Inc. He is a co-founder of Exelixis, Inc. In the not-for-profit sector, Dr. Papadopoulos is a member of the Board of Visitors of Duke Medicine. He spent six years (2000-2006) at Cowen & Co., LLC, most recently as vice chairman, where as an investment banker, he focused on the biotech and pharma sectors.
Parag Saxena, our CEO, has extensive investment experience in the U.S. and in the Indian subcontinent. Mr. Saxena co-founded Vedanta Management L.P. and New Silk Route Advisors L.P., private equity investment management firms, in 2006 ,which currently collectively manage over $600 million in assets. He is the managing partner and CEO of both firms. Chief Executive Officer of both firms
An affiliate of our sponsor, Vedanta Management, is a leading healthcare and technology focused investment firm. The members of the team at Vedanta (including their time at Invesco and its predecessor firms) have been early backers (first institutional check/early investor) of transformative companies in key sectors: healthcare (Celgene, Amgen, Masimo, Genomic Health, Parexel, ICOS Pharmaceuticals), technology (Metro PCS, ARM, Polycom), and consumer (Starbucks, Costco).
|Address||250 West 55th Street, Suite 13D New York, New York 10019|
|Phone Number||(212) 710-5220|
|View Prospectus:||Eucrates Biomedical Acquisition Corp.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$100.0 mil|
|Manager / Joint Managers||Stifel/ H.C. Wainwright & Co.|
|Expected To Trade:||10/23/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|